Correspondence 0001493152-24-027151 from Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals, Inc.
Date: July 12, 2024 · CIK: 0001583771 · Accession: 0001493152-24-027151

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-280752

Date

July 11, 2024

Author

Not clearly detected

Form

CORRESP

Company

Hepion Pharmaceuticals, Inc.

Letter

Hepion Pharmaceuticals, Inc.

Thornall Street, First Floor

Edison, NJ 08837

July 12, 2024

VIA EDGAR

United States Securities and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Jimmy McNamara

Re: Hepion Pharmaceuticals, Inc.

Form S-1 Registration Statement

Filed July 11, 2024

File No. 333-280752

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Standard Time, on Monday, July 15, 2024, or as soon thereafter as possible.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

HEPION PHARMACEUTICALS, INC.

By: /s/ John Cavan

Name: John Cavan

Title: Interim Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

Hepion
Pharmaceuticals, Inc.

399
Thornall Street, First Floor

Edison,
NJ 08837

    July
    12, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Jimmy McNamara

    Re:
    Hepion
    Pharmaceuticals, Inc.

    Form
    S-1 Registration Statement

    Filed
    July 11, 2024

    File
    No. 333-280752

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective
at 4:30 p.m., Eastern Standard Time, on Monday, July 15, 2024, or as soon thereafter as possible.

Please
notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible
as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

    HEPION
    PHARMACEUTICALS, INC.

    By:
    /s/
    John Cavan

    Name:
    John
    Cavan

    Title:
    Interim
    Chief Executive Officer

SecProbe.io